SCHEMBL2912643

SCHEMBL2912643

CCOc1ccc(NC=C(C(=O)O)C(=O)O)cc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.44
NPC1 O15118 2/20 0.43
MAPK1 P28482 1/20 0.43
DHODH Q02127 2/20 0.43
HSD17B10 Q99714 2/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
NR4A1 P22736 1/20 0.42
TSHR P16473 1/20 0.42
P2RX3 P56373 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
RORC P51449 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3944683 0.87 DHODH (0.60) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL2904221 0.85 ALDH1A1 (0.47) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL7291739 0.84 GAA (0.50) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL63413 0.77 NPC1 (0.56) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL2908095 0.76 GRM4 (0.47) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL16870635 0.74 DHODH (0.54) MAPTKMT2AMEN1ALDH1A1KDM4E
Butane SCHEMBL5575001 0.74 NPC1 (0.53) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL10861060 0.74 DHODH (0.65) MAPTKMT2AMEN1KDM4EMAPK1
SCHEMBL5706881 0.74 GAA (0.61) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL10861648 0.72 DHODH (0.67) MAPTKMT2AMEN1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 EP disclosed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 MAPT 3289/4885KMT2A 273/4885MEN1 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.